PMID

Data

Article Title

Organization

Discovery of a novel Kv7 channel opener as a treatment for epilepsy.

Pfizer

Novel KCNQ2/Q3 agonists as potential therapeutics for epilepsy and neuropathic pain.

Icagen

Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.

Vanderbilt University Medical Center

N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

TBA

Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.

Hebei Medical University

Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.

Abbott Laboratories

(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.

Bristol-Myers Squibb Pharmaceutical Research Institute

Synthesis and Optimization of K

University of Pittsburgh

Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.

University Federico Ii of Naples

Design and evaluation of pyrazolopyrimidines as KCNQ channel modulators.

Abbvie

Potassium channel modulators as possible treatment for pain: patent highlight.

Therachem Research Medilab (India)

Novel K

Glaxosmithkline

Discovery of a Series of Indazole TRPA1 Antagonists.

Pfizer